SAGE News and Press, Sage Therapeutics Inc. From 02/28/23

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Cowen 43 rd Annual Health Care Conference on Monday, March 6, 2023, at 10:30 a.m. ET in Boston, MA. A live w...

The European Medicines Agency (EMA) granted orphan drug designation to Sage Therapeutics' ( NASDAQ: SAGE ) medicine  SAGE-718 to treat Huntington's disease (HD). The company said SAGE-718 is being developed as an oral therapy for cognitive disorders linked with NMDA receptor...

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today announced the European Medicines Agency (EMA) granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington’s disease (HD). SAGE-718 is in dev...

Summary Sage’s first approved drug, Zulresso, did not sell well. Zuranolone offers significant improvements for depression over current therapies. While some success is built into the stock price, an FDA approval should lead to both short and long-term gains, given the size o...

Sage Therapeutics, Inc. (SAGE) Q4 2022 Earnings Conference Call February 16, 2023 8:00 AM ET Company Participants Helen Rubinstein - Director of Investor Relations Barry Greene - Chief Executive Officer Jim Doherty - Chief Development Officer Chris Benecchi - Chief...

The following slide deck was published by Sage Therapeutics, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Sage Therapeutics, Inc. 2022 Q4 - Results - Earnings Call Presentation

Sage Therapeutics press release ( NASDAQ: SAGE ): Q4 GAAP EPS of -$2.47 misses by $0.08 . Revenue of $2.9M (+81.3% Y/Y) beats by $0.96M . Cash, cash equivalents and marketable securities as of December 31, 2022 were $1.3 billion compared to $1.4 billion at September 30...

U.S. Food and Drug Administration (FDA) accepts filing of New Drug Application (NDA) for zuranolone and grants Priority Review in the treatment of Major Depressive Disorder (MDD) and Postpartum Depression (PPD) following submission of rolling NDA in December 2022 Robust pipeli...

Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD) Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWI...

Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD) Depression is a public health issue with significant unmet medical need Sage Therapeutics, Inc. (Nasdaq: SAGE) and ...